Diacerein is an slow-onset anthraquinone IL-1 inhibitor used in the treatment of degenerative joint diseases like osteoarthritis. Diacerein is a prodrug which is metabolized to rhein.
- Mechanism
- Curator reviewed · 3 references
Diacerein's active metabolite rhein DB13174 reduces cartilage destruction by decreasing expression of matrix metalloproteinase (MMP)-1 and -3 as well as upregulating tissue inhibitor of matrix metalloproteinases which serve to reduce the activity of several MMPs. The anti-inflammatory action of rhein reduces the level of interleukin-1beta activity which plays a large role in reduction of extracellular matrix production, MMP activity, and continued inflammation. Rhein reduces abnormal osteoblast synthetic activity through an unknown mechanism.
- Primary indication
- For the treatment of osteoarthritis affecting the hip or knee.Curator reviewed · 2 structured indications
- Formula / weight
- C19H12O8 · 368.297 g/mol (avg)
- Code names
- AC-201 · SF-277
Resolves to
TYNLGDBUJLVSMA-UHFFFAOYSA-NSMILESCC(=O)OC1=CC=CC2=C1C(=O)C1=C(OC(C)=O)C=C(C=C1C2=O)C(O)=OWhat you can answer from here — as of March 06, 2025
Which drugs share a target with Diacerein, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account